BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Conceptus, Inc. 

331 East Evelyn Avenue

Mountain View  California  94041  U.S.A.
Phone: 650-962-4000 Fax: 650-962-5151


View Clinical Trials from BioPharm Insight

Founded in 1992, Conceptus (CPTS) is engaged in the design, development and marketing of innovative medical products for use in the field of women's health.

Conceptus is currently focused on marketing its EssureĀ® permanent birth control system worldwide. With Essure, Conceptus believes it has the technology to transform the field of permanent birth control, and is in the process of marketing Essure globally.

In 2002, the U.S. Food and Drug Administration granted approval in November, 2002 to market Essure in the United States, a market where 700,000 tubal ligations and 400,000 vasectomies are performed annually.

The Essure procedure is a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide.

Tubal ligation involves abdominal incisions, general anesthesia, four to six days of recovery time and the risks associated with an incisional procedure.

The Essure procedure does not require incisions or general anesthesia. Essure can be performed in an outpatient setting, and women who have the procedure usually resume regular activities within 24-48 hours after the day of the procedure.

Essure is approved for sale in many countries, including the United States, Europe, Australia, Canada, Mexico, Central and South America, and New Zealand. Conceptus is working to make Essure available world-wide upon receipt of appropriate regulatory and/or governmental clearances.

Headquartered in the United States, Conceptus has twice been awarded "Fastest Growing Business in Silicon Valley (California).

Last Updated: 05-15-2007

 Key Statistics

Ownership: Public

Web Site: Conceptus, Inc.
Symbol: CPTS

Medical Device

 Company News
Complications From Conceptus, Inc. (CPTS)'s Essure Birth Control Reported 12/23/2013 8:42:36 AM
Bayer AG (BAY.F) Acquires Conceptus, Inc. (CPTS) for $1.1 Billion 6/7/2013 8:14:45 AM
Antitrust Clearance Obtained for Bayer Corporation (BAY)'s Acquisition of Conceptus, Inc. (CPTS) 5/29/2013 10:02:45 AM
Bayer HealthCare (BAY) Commences Cash Tender Offer for All Outstanding Shares of Conceptus, Inc. (CPTS) 5/8/2013 10:11:17 AM
Bayer AG (BAY.F) to Buy Birth-Control Device Maker Conceptus, Inc. (CPTS) for $1.1 Billion 4/29/2013 7:48:40 AM
Conceptus, Inc. (CPTS) Names Joseph G. Sharpe as Executive Vice President of Operations 1/22/2013 9:17:52 AM
Conceptus, Inc. (CPTS) to Hold Fourth Quarter Financial Results Conference Call on February 5, 2013 1/8/2013 9:08:49 AM
Conceptus, Inc. (CPTS) Praises France's UNCAM Decision to Remove Age Restrictions on Reimbursement for Essure® Permanent Birth Control 11/14/2012 9:41:11 AM
Conceptus, Inc. (CPTS) to Highlight Expert OB/GYN Committee's Recommendation That Hysteroscopic Sterilization Become "Best Practice" for Female Sterilization at 41st AAGL Global Congress of Minimally Invasive Gynecology 11/7/2012 9:24:13 AM
Conceptus, Inc. (CPTS) to Participate in Three Investor Conferences 10/26/2012 6:35:00 AM